Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

(2019) Michael J Birrer et al.   JNCI-Journal of the National Cancer Institute

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

(2019) Scott T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy

(2019) Takashi Nakada et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo

(2019) Jinrong Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.

(2019) Scott T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

(2018) Kathleen N Moore et al.   Future Oncology

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

(2018) Gentry T. King et al.   INVESTIGATIONAL NEW DRUGS

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

(2018) Tomomi Nakayama Iwata et al.   MOLECULAR CANCER THERAPEUTICS

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

(2018) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd.

(2018) Daisuke Okajima et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

(2018) Meghdad Abdollahpour-Alitappeh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance

(2017) Naoki Takegawa et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

(2017) Robert M. Sharkey et al.   MOLECULAR CANCER THERAPEUTICS

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma

(2016) Bishoy Faltas et al.   Clinical Genitourinary Cancer

Prospects and progress of antibody-drug conjugates in solid tumor therapies

(2016) Serengulam V. Govindan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

(2016) P. Strop et al.   MOLECULAR CANCER THERAPEUTICS

The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer

(2016) Yuan Mao et al.   Oncotarget

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

(2015) Thomas M. Cardillo et al.   BIOCONJUGATE CHEMISTRY

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)

(2015) R. M. Sharkey et al.   CLINICAL CANCER RESEARCH

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

(2015) Pavel Strop et al.   NATURE BIOTECHNOLOGY

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Antibody-drug conjugates: an emerging modality for the treatment of cancer

(2014) Mauricio Leal et al.   Annals of the New York Academy of Sciences

A novel human Fab antibody for Trop2 inhibits breast cancer growthin vitroandin vivo

(2013) Hong Lin et al.   INTERNATIONAL JOURNAL OF CANCER

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody

(2011) Joyce Varughese et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

(2011) T. M. Cardillo et al.   CLINICAL CANCER RESEARCH

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma

(2011) Eliana Bignotti et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma

(2011) Quan-Yi Guo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Trop2: A possible therapeutic target for late stage epithelial carcinomas

(2009) Rafael Cubas et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates

(2009) S. V. Govindan et al.   CLINICAL CANCER RESEARCH

Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

(2009) Alexander Stein et al.   Therapeutic Advances in Medical Oncology

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy

(2008) Sung-Ju Moon et al.   JOURNAL OF MEDICINAL CHEMISTRY